Get started
Author

Kotomi Akatsuka

ORCID: 0009-0000-8606-3018
Observed ORCID: 0009-0000-8606-3018
OpenAlex ID: A5028853044
Tamoxifen inhibits the proliferation of non‑melanoma skin cancer cells by increasing intracellular calcium concentration
2018 · Go Hasegawa, Kotomi Akatsuka, et al. · International Journal of Oncology · 15
PDF
Anti‑proliferative effect of ridaifen‑B on hepatoma cells
2018 · Go Hasegawa, Kotomi Akatsuka, et al. · Biomedical Reports · 1
PDF
Supplementary Figure S2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S3 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Table S2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S6 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S4 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Table S1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S7 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S5 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Data from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Table 1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Table S2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Figure 4 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Table 2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S3 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S7 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Figure 3 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Figure 5 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Table S1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S4 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Figure 2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Works count: 33
Citation count: 16
H-index: 1
I10-index: 1
Year
Topic
Type